Condition: Primary Myelofibrosis · Post-polycythemia Vera Myelofibrosis · Post-essential Thrombocythemia Myelofibrosis · Sponsor: Swedish Orphan Biovitrum
This study (study ID PAC203 North America; PAC303 ex-North America) is evaluating 200 mg BID of pacritinib compared to physician's choice (P/C) therapy in patients with MF and severe thrombocytopenia (platelet count \<50,000/μL). Approximately 399 patients in total will be enrolled, randomized 2:1 to either pacritinib (approximately 266 patients) or to P/C therapy (approximately 133 patients) Condition or disease: Primary Myelofibrosis/Post-Polycythemia Vera Myelofibrosis/ Post-essential Thrombocythemia Myelofibrosis Intervention/treatment: Drug-Pacritinib
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| University of Alabama at Birmingham, (UAB) Hospital, Comprehensive Cancer Center | Birmingham, Alabama, United States | — |
| Mayo Clinic Hospital | Phoenix, Arizona, United States | — |
| City of Hope | Duarte, California, United States | — |
| USC Norris Comprehensive Cancer Center | Los Angeles, California, United States | — |
| UCLA David Geffen School of Medicine | Los Angeles, California, United States | — |
| University of Colorado Cancer Center | Aurora, Colorado, United States | — |
| Rocky Mountain Cancer Centers (US Oncology/McKesson) | Boulder, Colorado, United States | — |
| Yale School of Medicine | New Haven, Connecticut, United States | — |
| Georgetown University Hospital | Washington D.C., District of Columbia, United States | — |
| George Washington University-Medical Faculty Associates | Washington D.C., District of Columbia, United States | — |
| Cleveland Clinic Florida | Weston, Florida, United States | — |
| Northwestern Memorial Hospital | Chicago, Illinois, United States | — |
+ 195 more locations — full list on the registry record.
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.